Oskar Slotboom
Managing Partner @ BioGeneration Ventures
Naarden, The Netherlands
Oskar Slotboom is a Series A investor at BioGeneration Ventures in Naarden focused on Therapeutics and Biotechnology. Oskar Slotboom is based out of Naarden, North Holland and is the Managing Partner of BioGeneration Ventures. Oskar previously worked at Avantium as a Chief Commercial Officer. Oskar Slotboom attended the INSEAD .
- Total investments:
- 6
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Oskar Slotboom invests in
Stages Oskar Slotboom invests in
Countries Oskar Slotboom invests in
Investment Focus
Industry
- Therapeutics 3 (50%)
- Biotechnology 2 (33%)
- Manufacturing 2 (33%)
- Pharmaceutical 2 (33%)
- Medical 1 (17%)
Stage
- Series A 2 (33%)
- Series C 2 (33%)
- Seed 1 (17%)
- Series B 1 (17%)
Country
- The Netherlands 3 (50%)
- Germany 1 (17%)
- United Kingdom 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
CatalYm
|
Catalym develops antibodies against a placental factor which is overexpressed by various tumour types. | $51.6M / Series C / Nov 22, 2022 | |
NorthSea Therapeutics
|
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generatedpipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models. | $80M / Series C / Dec 17, 2021 | |
Dunad Therapeutics
|
Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies. | $24M / Series A / Nov 02, 2021 | |
VarmX
|
VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer. | $8.2M / Series A / Jul 02, 2018 | |
Mellon Medical
|
Mellon Medical provides suturing tools for surgeons to improve medical procedures. The company's goal is to help medical specialists improve patient outcomes by providing them with the best possible suturing tools. It commercializes surgical instruments to allow single-handed stitching, enabling efficient and effective suturing of tubular andlayered structures.Mellon Medical was established in 2013 and is headquartered in Nijmegen, Gelderland. | $6.4M / Series B / Aug 30, 2017 | |
|
VarmX
|
VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer. | $1.1M / Seed / Jun 27, 2017 |
Co-Investors
About BioGeneration Ventures
BioGeneration Ventures is investing in the next generation of Life Sciences companies in the Netherlands. BioGeneration Ventures invests in Dutch start-up and early stage life sciences companies. The BioGeneration Ventures team is specialized in the evaluation and management of early stage companies. Their involvement goes beyond thefinancial investment. They work closely with scientists, academic institutions, entrepreneurs and industry experts to accelerate the development and to optimize the commercial potential of their portfolio company's technologies. BioGeneration Ventures began operating in 2006 and the fund is backed by the Netherlands Genomics Initiative (NGI) and the Netherlands Organisation for Scientific Research (NWO) in combination with the holding company of Leiden University and ABN-AMRO Capital as lead private investors.
BioGeneration Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Daniela Couto
General Partner
|
|||
Edward van Wezel
Founder and Managing Partner
|
|||
Joost Holthuis
Venture Partner
|
|||
|
Oskar Slotboom
Managing Partner
|
|||
Elena Ritsou
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Oskar Slotboom invest in?
Oskar Slotboom invests primarily in Therapeutics, Biotechnology and Manufacturing startups, most often at Series A and Series C stage. Most of the 6 investments tracked by Shizune back companies in The Netherlands. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Oskar Slotboom last invest?
The most recent investment recorded for Oskar Slotboom closed in Nov 2022. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
